MRSA bacteraemia (MRSAB), including infective endocarditis, carries a high mortality rate, with up to 50% of patients failing initial therapy with vancomycin and requiring salvage therapy. Persistent MRSAB can be difficult to successfully eliminate, especially when source control is not possible due to an irremovable focus or the bacteraemia still persists despite surgical intervention. Although vancomycin and daptomycin are the only two antibiotics approved by the US FDA for the treatment of patients with MRSAB as monotherapy, the employment of novel strategies is required to effectively treat patients with persistent MRSAB and these may frequently involve combination drug therapy. Treatment strategies that are reviewed in this manuscript include vancomycin combined with a b-lactam, daptomycin-based therapy, ceftaroline-based therapy, linezolid-based therapy, quinupristin/dalfopristin, telavancin, trimethoprim/sulfamethoxazole-based therapy and fosfomycin-based therapy. We recommend that combination antibiotic therapy be considered for use in MRSAB salvage treatment.
Introduction
The IDSA 2011 MRSA guidelines recommend vancomycin or daptomycin, each approved by the US FDA for MRSA bacteraemia (MRSAB), for first-line MRSAB therapy. 1 Although definitions vary, treatment failure is encountered in up to 50% of cases. 2 There are multiple reasons for treatment failure including poor source control, inadequate surgical debridement, host innate immunity deficiency and antibiotic pharmacodynamic factors. Irrespective of the reason, MRSAB treatment failure per se is linked to poorer outcomes, including a greater likelihood of metastatic infections and increased mortality. 3, 4 The IDSA guidelines recommend switching to an alternative agent rather than adding to a failing (defined as persistent bacteraemia at or around 7 days, but earlier if clinical deterioration is present) regimen. 1 However, these patients represent a complex heterogeneous group with sparse data addressing how they should be optimally treated. The objective of this paper is, therefore, to review MRSAB treatment options for patients requiring salvage therapy.
Methods
We evaluated all adult English-language peer-reviewed articles including case series that examined salvage therapy, defined as a change of therapy for ≥72 h to a new active agent(s) due to failure (as determined by the authors) of the initial treatment for MRSAB, including infective endocarditis (IE). Articles were identified through PubMed, EMBASE and the Cochrane Library (see the Search terms section and Tables 1 and 2 ).
Search terms
The following terms and connectors were included in the search strategy: 'Staphylococcus aureus' or 'S. aureus' or 'methicillin resistant Staphylococcus aureus', and 'salvage' or 'treatment failure' and 'vancomycin', 'daptomycin', 'ceftaroline', 'linezolid', 'quinupristin/dalfopristin', 'telavancin', 'trimethoprim/ sulfamethoxazole', 'fosfomycin'.
Salvage therapy options

Vancomycin1 b-lactam
In vitro studies have demonstrated synergistic activity between vancomycin and several b-lactams against S. aureus, including MRSA. 5, 6 This observed synergy extends to heterogeneous vancomycin-intermediate S. aureus (hVISA) and VISA isolates, with several studies observing reduced total vancomycin binding (but potentially greater target-specific binding) to the cell wall and reduced cell wall thickness following exposure to ceftaroline and oxacillin or nafcillin, respectively. 5, 7, 8 Vancomycin is synergistic with a variety of penicillinase-stable b-lactams in vitro. In a small number of VISA and hVISA strains, ceftaroline appeared more reliably synergistic with vancomycin than did oxacillin. 5 Further benefit from the addition of a b-lactam may accrue from the ability of these agents to potentiate cationic host defence peptides (HDPs). 9 Since vancomycin is generally considered the first-line treatment option for most MRSA infections, published experience with the use of vancomycin alone or in combination with a b-lactam as salvage therapy is limited. Vancomycin combined with a b-lactam at or near the initiation of therapy, however, has been reported to yield improved results compared with vancomycin monotherapy. A retrospective study found that MRSAB microbiological eradication was achieved in 48/50 patients (96%) who received vancomycin with a b-lactam (piperacillin/tazobactam; 34/50) compared with 24/30 patients (80%) (P¼0.021) who received vancomycin monotherapy; combination therapy was an independent predictor of microbiological success. 10 However, combination therapy was initiated for the treatment of possible polymicrobial infections, not specifically for the treatment of MRSAB, and thus did not constitute salvage therapy.
Barber et al. 11 presented a case of a haemodialysis patient with septic subclavian thrombophlebitis who failed treatment of relapsed MRSAB with high-dose daptomycin (12 mg/kg) plus ceftaroline (400 mg every 8 h), with the daptomycin MIC increasing from 0.5 to 2 mg/L. Vancomycin was subsequently substituted for daptomycin with continuation of ceftaroline and bacteraemic clearance within 24 h. Time-kill studies demonstrated that vancomycin combined with ceftaroline was more potent than daptomycin plus ceftaroline, leading to the authors' conclusion that in the absence of heteroresistance to vancomycin, ceftaroline combined with vancomycin rather than daptomycin may be preferred.
Recently, results from an open-label, multicentre trial from Australia supported the use of a b-lactam with vancomycin for MRSAB, with 60 patients randomly assigned to receive vancomycin (n ¼ 29) or vancomycin plus flucloxacillin (n ¼ 31). The mean duration of bacteraemia was shorter in the combination versus standard therapy group (1.94 versus 3 days), with fewer patients having persistence at days 3 and 7 in the combination arm.
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Daptomycin1 b-lactam
In vitro analyses have shown that b-lactams impact the surface charge of MRSA, enhancing daptomycin binding and resulting in synergistic killing.
13,14 b-Lactams with PBP-1 binding (e.g. meropenem, ampicillin, nafcillin, cefepime and piperacillin/tazobactam) appear to enhance daptomycin anti-MRSA activity the most. 15 Combining a second antibiotic with daptomycin in vitro also slows the loss of susceptibility to daptomycin. 16, 17 Sakoulas et al. 18 reported the results of salvage therapy in persistent (median 10 days; range 3-23 days) S. aureus bacteraemia with daptomycin plus ceftaroline therapy in 26 patients. The most common source of bacteraemia was IE (n ¼ 14; left-sided, 12 patients) with 22 infections due to MRSA. Of these, two were vancomycin intermediate while four isolates were daptomycin non-susceptible (DNS). Upon initiation of daptomycin plus ceftaroline, bacteraemia cleared in a median of 2 days (range 1 -6 days). In vitro analysis showed ceftaroline offered a potential dual benefit not only by its favourable interaction with daptomycin, but also by sensitization of MRSA to the innate HDP cathelicidin LL37. A recent study by Barber et al. 19 confirmed this synergistic activity in an in vitro biofilm model, revealing that this combination displayed therapeutic enhancement against MRSA biofilms.
Single case reports and a series of seven cases indicated similar success in MRSAB salvage therapy with daptomycin combined with a b-lactam.
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High-dose daptomycin
Daptomycin is approved by the FDA for the treatment of S. aureus bacteraemia and right-sided IE at 6 mg/kg/day. 2 Non-susceptibility may, however, emerge when daptomycin is administered at this dose, particularly when given after vancomycin treatment failure in cases of high inoculum infections, IE and device infections. 22 Daptomycin heteroresistance may occur even in the absence of 24 Consequently, the IDSA MRSAB treatment guidelines recommend daptomycin to be dosed at 10 mg/kg/day when used as monotherapy. 1 Moreover, the recently published 2015 European Infective Endocarditis treatment guidelines recommend daptomycin to be dosed at ≥10 mg/kg/day and combined with a second antibiotic (a b-lactam or fosfomycin) to increase activity and avoid the development of resistance. 60 Kullar et al. 25 reported the results of high-dose daptomycin therapy for complicated Gram-positive infections, with 184/250 patients receiving this agent as salvage therapy after vancomycin failure. MRSA was the most common pathogen isolated (57.8%) and 54.4% were bacteraemic. Ninety-one patients (36.4%) received daptomycin at ≥10 mg/kg/day. Overall, 209/250 (83.6%) patients had clinical success and the organism was eradicated in 175/218 (80.3%). There was no significant correlation between daptomycin dose (mg/kg) and the highest observed creatine phosphokinase level while receiving therapy (r s ¼0.042, P¼0.63). Similar success and safety rates were found in a study conducted by the same group evaluating high-dose daptomycin in patients with IE. 26 Lai et al. 27 evaluated the use of high-dose daptomycin in patients with serious Gram-positive infections, with 63/67 (94%) patients receiving high-dose daptomycin as salvage therapy. MRSA was isolated in 56.7% patients and 80.6% patients were bacteraemic. The overall clinical and microbiological success rates were 77.6% and 82.1%, respectively.
Although these and other 28 -30 retrospective studies have shown high-dose daptomycin to be safe and efficacious in MRSAB salvage therapy, a comparator trial between high-and standard-dose daptomycin in MRSAB treatment failure is warranted.
Ceftaroline
Ceftaroline is distinguished from other b-lactams by its uniquely high binding affinity for PBP-2a, thus conferring its activity against MRSA. 31 There has been increasing off-label ceftaroline use for the treatment of MRSAB including IE, particularly for salvage therapy.
In the largest retrospective evaluation of patients treated with ceftaroline, clinical success was reported in 101/129 (78.3%) patients with S. aureus (92.5% MRSA) bacteraemia, 92% of whom had IE. 32 These patients were part of a larger cohort of 527 ceftaroline recipients, 80% of whom initially received another antibiotic (most commonly vancomycin), with the most frequent reason for the switch being 'disease progression', accounting for the change in 48% of patients. Forty-one of 527 (7.8%) patients experienced an adverse event, with renal failure being the most common. Notably, 13/76 patients (17.1%) receiving an off-label dose experienced an adverse event. The interpretation of these results with regard to the efficacy of ceftaroline as salvage monotherapy is, however, problematic since the proportion of bacteraemic patients who received a combination therapy with ceftaroline is uncertain and the number of patients still bacteraemic at the time of switch is unknown.
Polenakovik and Pleiman 33 evaluated ceftaroline use in 31 patients, 9 of whom had IE (mostly right-sided). The vancomycin MIC (via microbroth dilution) for all but 2 patients was 2 mg/L and this was the primary reason for an antibiotic switch in 14 patients. Only 10 patients had bacteraemia persisting for .7 days during initial therapy with vancomycin or daptomycin while another 2 had recurrent infections-these 12 constituted the potential salvage group. Microbiological cure was documented in 20 patients (64.5%) with the true rate likely greater since not all had microbial tests of cure. Clinical success was achieved in 74.2%. In the three patients who had recurrent MRSAB despite ceftaroline therapy, all were related to retained prosthetic material.
Overall, these clinical data and five recently published 34 -38 case reports support the use of ceftaroline as an option for MRSAB salvage therapy. In contrast to salvage therapy with daptomycin, there has been no observed association of prior vancomycin exposure and ceftaroline failure. Several patients in the studies mentioned above received doses higher than the FDA-approved dose (600 mg every 12 h) with increased rates of adverse effects. Further studies are warranted to determine the safety and added benefit of this higher total daily dose. Additionally, details of a completed prospective cohort study of ceftaroline (600 mg every 8 h) including patients with persistent MRSAB are expected and may further refine ceftaroline recommendations, although its noncomparative nature may preclude definitive conclusions. 39 
Linezolid
Although the bacteriostatic nature of linezolid is considered by many to preclude its use in IE, the IDSA guidelines mention linezolid as among the options for MRSAB salvage therapy. 1 In a linezolid compassionate access programme, 40 40 patients with MRSAB who had failed (n¼11) or were intolerant (n¼29) to vancomycin were given linezolid. Clinical success was achieved in 18/21 (83.7%) of bacteraemic patients and in 3/4 patients with IE. Linezolid therapy was continued for a median of 28 days with an adverse event leading to discontinuation in 18.3% cases.
In a study of patients with confirmed hVISA bacteraemia, 19/25 patients (76%) failed empirical vancomycin therapy and 60% (15/ 25) had persistent bacteraemia (7-32 days). 41 Sources of bacteraemia included IE and osteomyelitis, usually in the setting of a prosthetic device. Linezolid monotherapy was prescribed as the sole salvage agent in five cases, with subsequent microbiological clearance occurring in four patients. Of the remaining 10 episodes, 7 were treated with regimens that included linezolid alone as part of sequential therapy or in combination with other agents such as rifampicin. Overall effective therapy was observed in 8/12 cases (67%). Treatment success generally occurred in those patients who also underwent surgical intervention. Several patients experienced adverse events (32%) with a median duration of linezolid therapy of 41 days (7-78 days).
Jang et al. 42 evaluated patients who required salvage therapy for S. aureus bacteraemia persistence. Of 377 patients with S. aureus bacteraemia, 41 cases (11%) were persistent despite administration of appropriate antibiotics. Thirty-five of the 41 persistent bacteraemia patients had persistence due to MRSA, with further treatment details available for 28 patients. Salvage therapy consisted of either the addition of an aminoglycoside or rifampicin to vancomycin (n ¼ 12) or vancomycin substitution with linezolid (n ¼ 16) alone (n ¼ 7) or in combination with a carbapenem (n¼ 9). The observed vancomycin dosing would, by current standards, be considered suboptimal with trough levels ,15 mg/L in approximately half the patients. Nevertheless, linezolid substitution was significantly more effective, with MRSA clearance in 75% compared with 17% with vancomycin-based therapy continuation Review (P¼0.006). Thrombocytopenia developed in 7/12 (58%) evaluable patients in the linezolid group, resulting in a switch back to vancomycin in these patients. Two of these seven patients had bacteraemia recurrence and were successfully treated with readministration of linezolid.
Park et al. 43 undertook a prospective observational study, with propensity matching, evaluating salvage therapy in patients with persistent MRSAB, where patients were continued on a vancomycinbased regimen or linezolid was substituted for vancomycin with or without a carbapenem. Of 377 MRSAB episodes, 90 (24%) were persistent, and 38 (42%) were switched to linezolid monotherapy (n¼19) or together with a carbapenem (n¼19) after persistence of bacteraemia for a median of 16 days (range 10-24 days). Early microbiological response and treatment success was achieved in 17 (45%) and 28 (74%) patients, respectively. Linezolid-based patients had a significantly lower 30 day mortality compared with glycopeptide-based patients (11% versus 25%; P¼0.008).
Several case reports have been published using linezolid successfully in persistent MRSAB cases. 44, 45 These data suggest that linezolid may be a viable option in salvage therapy, at least in the absence of IE; however, due to the prolonged course of therapy bacteraemic patients may require, clinicians should be cautious with linezolid's reversible myelosuppressive effects and should closely monitor patients' complete blood counts.
Quinupristin/dalfopristin
Quinupristin/dalfopristin was used as salvage therapy in 12 critically ill patients who had failed vancomycin therapy. Nine patients had MRSA infections, with seven being bacteraemic. Microbiological clearance was obtained in 77% (7/9) with all persistent bacteraemia patients (n¼4) clearing their bloodstream. 46 Quinupristin/dalfopristin use is generally limited even in salvage settings due to the substantial rate of adverse events and need for a central venous catheter for administration. Furthermore, resistance to macrolides-lincosamides-streptogramins mediated by ribosomal methylation (e.g. erm) that is present in most healthcare-related MRSA strains involved in persistent bacteraemia renders quinupristin/dalfopristin, a bacteriostatic antibiotic, an unfavourable property in bacteraemia therapy, particularly in IE. 47 
Telavancin
Although lipoglycopeptides, such as telavancin, act by inhibiting cell wall biosynthesis, they also rapidly depolarize the cell membrane leading to cell death. This additional mechanism of action results in greater in vitro bactericidal activity and increased potency compared with vancomycin. 48 These agents also retain activity against hVISA, VISA and DNS isolates. 49 Consequently, they may be effective options since DNS isolates may arise during vancomycin failure. In a recently published case series, 50 14 patients received telavancin as salvage therapy. Of the 14 patients, the median duration of bacteraemia prior to receiving telavancin was 12 days (range 3 -26 days). Eleven of the 14 had IE as their source of bacteraemia with 6 patients switched to daptomycin prior to commencing telavancin monotherapy. Ten of 14 patients became blood culture negative in a median of 1 day (1-3 days) following the initiation of telavancin, but 6 patients died, each of whom had mitral valve IE. Further studies are warranted to define the optimal role of telavancin in the treatment of MRSAB and IE.
Trimethoprim/sulfamethoxazole
Trimethoprim/sulfamethoxazole is a bactericidal agent with in vitro activity against MRSA. Although no studies have evaluated trimethoprim/sulfamethoxazole for MRSAB salvage therapy, a recent randomized controlled study of initial therapy 51 has cast doubts about its utility used alone in this setting since greater bacteraemic persistence was observed with trimethoprim/sulfamethoxazole monotherapy compared with vancomycin.
Recent studies have examined trimethoprim/sulfamethoxazole in combination with either daptomycin or ceftaroline. Trimethoprim/ sulfamethoxazole plus daptomycin exhibits potent synergy in vitro. 52, 53 These in vitro findings have been supported in noncomparative clinical case reports and case series, offering this combination as a viable option in MRSAB salvage therapy. 54 -56 A recent case series 57 evaluated the clinical outcomes of patients with MRSAB including IE that failed initial therapy and were switched to trimethoprim/sulfamethoxazole plus ceftaroline. Of 29 patients, 23 received the combination therapy, with the median duration of bacteraemia being 9.5 days (IQR ¼ 7 -15 days) before the switch and 3 days (IQR¼ 2 -5 days) after the switch. The most common source of infection was endovascular (65%), consisting of 15 cases with IE (4 right-sided, 11 left-sided). Microbiological success was achieved in 90%, with a success rate of only 31% (due in part to 25% patients lost to follow-up).
The dose employed in trimethoprim/sulfamethoxazole combination studies is frequently 10 -15 mg/kg/day (representing the dose of trimethoprim), in two to three divided doses. While showing some promise, trimethoprim/sulfamethoxazole use does warrant an element of caution due to potential haematological adverse effects, associated hyperkalaemia and the uncertainty surrounding dosing in renal insufficiency.
Fosfomycin
A multicentre trial was conducted in Spain consisting of 16 patients who were treated with 2 g of fosfomycin intravenously every 6 h plus 1 g of imipenem intravenously every 6 h as salvage treatment in MRSAB. 58 All patients cleared their blood within 72 h, with a clinical success rate of 69%, and the regimen was well tolerated. Fosfomycin may be increasingly relied upon as a component of combination salvage therapy for MRSAB in countries where the parenteral formulation is available. Currently, intravenous fosfomycin is not available in the USA, with only oral fosfomycin being available. Provided very low oral bioavailability, with resulting peak serum concentrations of ,10 mg/L, it is unlikely that oral fosfomycin will be useful as an MRSAB salvage agent. 59 
Future directions and conclusions
Before considering alternative antimicrobial options, clinicians should remember: (i) source control remains critical; (ii) administered antibiotics do not exert their effect in a vacuum but within a complex host; and (iii) there is inconsistency in the definition of first-line treatment failure to identify patients who may benefit most from salvage therapy.
Although various regimens have been suggested, the optimal therapeutic approach in a patient with MRSAB failing treatment remains unknown. Adding a second agent to an initial failing regimen (e.g. adding a b-lactam to vancomycin) has not been formally Review 583 JAC evaluated. Switching from vancomycin to another antimicrobial such as daptomycin or ceftaroline may be beneficial, but the study designs make it difficult to reach an unequivocal conclusion. Various data suggest that the daptomycin dose in this salvage setting should be 10 mg/kg/day, 1, 60 but no clinical studies demonstrating greater benefit from this higher versus standard dose exist. Similarly, switching to either daptomycin or ceftaroline and adding a second antibiotic (e.g. a b-lactam) may also prove beneficial, but the data to date are insufficient to make this assessment. Despite these uncertainties, a reasonable approach to the patient failing vancomycin therapy is to switch to either daptomycin or ceftaroline (assuming in vitro susceptibility) and, if bacteraemia persists, to consider adding a b-lactam antibiotic.
These uncertainties dictate the direction of necessary future investigations. We recommend a consistent definition for what constitutes clinically relevant MRSAB persistence on-therapy and to utilize this definition in clinical therapeutic trials. Randomized clinical trials are warranted to compare the switch from vancomycin to either daptomycin or ceftaroline with, in the case of continued MRSAB persistence, a further randomization to continue therapy or to add a b-lactam antibiotic. 
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